Nachrichten zur LISATA THERAP.INC.DL-,001 Aktie

Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has completed patient enrollment in all three cohorts of its Phase 1b/2a CENDIFOX…

Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has completed patient enrollment in all three cohorts of its Phase 1b/2a CENDIFOX…

Lisata Therapeutics Inc (NASDAQ:LSTA) has announced a collaboration and license agreement with Kuva Labs, a wholly owned subsidiary of Mi2…

Lisata Therapeutics Inc (NASDAQ:LSTA) has been awarded the title of ‘Specialized BioTherapeutics Company of the Year’ at the 2024 BioTech…

Lisata Therapeutics Inc (NASDAQ:LSTA) has been awarded the title of ‘Specialized BioTherapeutics Company of the Year’ at the 2024 BioTech…

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive to talk about the latest updates on its clinical trials and…

…

Lisata Therapeutics Inc (NASDAQ:LSTA) reported significant advancements across its clinical portfolio in the third quarter, with multiple key data readouts...…

Lisata Therapeutics Inc (NASDAQ:LSTA), the US-based clinical-stage pharmaceutical company, and Finnish immunotherapy developer Valo Therapeutics Oy have...…

Lisata Therapeutics Inc (NASDAQ:LSTA), the US-based clinical-stage pharmaceutical company, announced a preclinical research collaboration to explore a novel...…

Lisata Therapeutics Inc (NASDAQ:LSTA) chief medical officer Dr Kristen Buck discussed with Proactive a promising collaboration between the company and…

…

Lisata Therapeutics Inc (NASDAQ:LSTA) has entered a research agreement with the University of Cincinnati to study the use of its cyclic…

Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has started treatment of the first patient in the second-line cholangiocarcinoma (CCA) cohort…

Lisata Therapeutics Inc (NASDAQ:LSTA) announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to…

…

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo told shareholders that the company is coming off a quarter with “strong momentum”…

Lisata Therapeutics Inc (NASDAQ:LSTA) chief medical officer Kristen Buck joined Proactive to discuss the company’s new research collaboration with Haystack...…

…

Lisata Therapeutics Inc (NASDAQ:LSTA) has announced a research collaboration with Haystack Oncology using Haystack’s MRD technology to evaluate the efficacy...…

Lisata Therapeutics Inc (NASDAQ:LSTA) said it has completed enrollment in its Phase 2a BOLSTER trial for certepetide, a promising investigational…

Complete enrollment achieved nearly six months ahead of plan…

Lisata Therapeutics Inc (NASDAQ:LSTA) chief medical officer Kristen Buck talked with Proactive about encouraging preclinical results for their drug...…

Lisata Therapeutics Inc (NASDAQ:LSTA) has unveiled encouraging preclinical results for its drug candidate, certepetide, in intrahepatic cholangiocarcinoma,...…

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive to discuss a recent milestone for the company: the completion of…

…

Lisata Therapeutics Inc (NASDAQ:LSTA) announced it has completed enrollment in the pancreatic cancer cohort of its Phase 1b/2a CENDIFOX trial.…

Lisata Therapeutics Inc (NASDAQ:LSTA) finds itself in an extraordinary but not unusual position emblematic of the challenges faced by small-cap biotech...…

Lisata Therapeutics Inc (NASDAQ:LSTA) has received a Paediatric Investigation Plan (PIP) waiver from the European Medicines Agency (EMA) for its…

…

…

…

Lisata Therapeutics Inc (NASDAQ:LSTA) has ended its first quarter of 2024 with nearly $43.3 million in cash to fund its…

…

…

Achieves critical first step toward priority review voucher Achieves critical first step toward priority review voucher…

Earnings call: Lisata Therapeutics reports on clinical trials and finances…

…